Kala Pharmaceuticals (KALA) Price & Analysis

Compare

1,500 Followers

KALA Stock Chart & Stats

$1.31

-$0.34(-4.42%)

At close: Jan 08 4:00 PM EST

$1.31

-$0.34(-4.42%)

Day’s Range― - ―

52-Week Range$1.10 - $20.60

Previous CloseN/A

Volume15.45K

Average Volume (3M)1.94M

Market Cap

$9.20M

Enterprise Value$28.99M

Total Cash (Recent Filing)$31.94M

Total Debt (Recent Filing)$11.14M

Price to Earnings (P/E)―

Beta1.06

Next Earnings

Nov 17, 2025

EPS Estimate

-1.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.71

Shares Outstanding7,021,040

10 Day Avg. Volume624,022

30 Day Avg. Volume1,940,241

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap3.15

Enterprise Value/Revenue114.14

Enterprise Value/Gross Profit-408.32

Enterprise Value/Ebitda-0.81

Forecast

1Y Price Target

$8.25

Price Target Upside529.77% Upside

Rating ConsensusHold

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Analyst ConfidenceAnalyst reiterates Buy rating and raises the 12-month price target to $35 per share, reflecting increased confidence in KPI-012's potential.

Market OpportunityWith no FDA approved treatment for PCED, KPI-012 could unlock real commercial potential.

Trial DesignThe unique 1-week run-in design of KALA's trial could lower the placebo effect, which is often a challenge in this space.

Bears Say

Clinical Trial ResultsThe CHASE trial of KPI-012 did not meet the primary endpoint of complete healing of PCED and failed to achieve statistical significance for key secondary efficacy endpoints.

Financial StabilityThe company's workforce is being reduced by approximately 51%, indicating potential financial or strategic challenges.

Strategic DecisionsManagement decided to cease development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform due to the trial results.

Kala Pharmaceuticals News

Kala Bio downgraded to Neutral from Outperform at Mizuho

Mizuho downgraded Kala Bio (KALA) to Neutral from Outperform with a price target of $1.50, down from $30....

20d ago

KALA

Kala Bio downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen downgraded Kala Bio (KALA) to Neutral from Buy without a price target Published...

21d ago

KALA

H.C. Wainwright downgrades Kala Bio to Neutral after CHASE trial miss

As previously reported, H.C. Wainwright downgraded Kala Bio (KALA) to Neutral from Buy without a price target after...

21d ago

KALA

Kala Bio shared no details on study miss, says Mizuho

Mizuho analyst Graig Suvannavejh expects “material weakness” in Kala Pharmaceuticals shares today after the company announced that KPI-012...

21d ago

KALA

Kala Pharmaceuticals downgraded to Market Perform at LifeSci Capital

LifeSci Capital downgraded Kala Pharmaceuticals (KALA) to Market Perform from Outperform and removed the firm’s price target after...

21d ago

KALA

Kala Pharmaceuticals trading resumes

09:37 EDT Kala Pharmaceuticals (KALA) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

21d ago

KALA

Kala Pharmaceuticals trading halted, volatility trading pause

09:32 EDT Kala Pharmaceuticals (KALA) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

21d ago

KALA

Kala to cease development of KPI-012, evaluate strategic options

Based on the CHASE trial results, KALA plans to cease development of KPI-012 and its mesenchymal stem cell...

21d ago

KALA

Kala says CHASE Phase 2b KPI-012 trial did not meet primary endpoint

KALA BIO announced that its CHASE Phase 2b clinical trial of KPI-012 for the treatment of persistent corneal...

21d ago

KALA

Kala Pharmaceuticals Faces Default Notice from Oxford Finance

An update from Kala Pharmaceuticals ( ($KALA) ) is now available. On September 29, 2025, Kala Pharmaceuticals received...

19d ago

KALA

Kala Pharmaceuticals Halts KPI-012 Development After Trial Failure

Kala Pharmaceuticals ( ($KALA) ) has shared an update. On September 28, 2025, KALA BIO, Inc. announced its...

21d ago

KALA

Kala Pharmaceuticals Sets Date for Annual Meeting

Kala Pharmaceuticals ( ($KALA) ) has provided an update. On September 16, 2025, the Board of Directors of...

1M ago

KALA

Strategic Positioning and Trial Design Propel Kala Pharmaceuticals to ‘Buy’ Rating

LifeSci Capital analyst Francois Brisebois has maintained their bullish stance on KALA stock, giving a Buy rating yesterday....

1M ago

KALA

Kala Pharmaceuticals price target raised to $35 from $12 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Kala Pharmaceuticals (KALA) to $35 from $12 and keeps a...

1M ago

KALA

KALA FAQ

What was Kala Pharmaceuticals Inc’s price range in the past 12 months?

Kala Pharmaceuticals Inc lowest stock price was $1.10 and its highest was $20.60 in the past 12 months.

What is Kala Pharmaceuticals Inc’s market cap?

Kala Pharmaceuticals Inc’s market cap is $9.20M.

When is Kala Pharmaceuticals Inc’s upcoming earnings report date?

Kala Pharmaceuticals Inc’s upcoming earnings report date is Nov 17, 2025 which is in 28 days.

How were Kala Pharmaceuticals Inc’s earnings last quarter?

Kala Pharmaceuticals Inc released its earnings results on Aug 08, 2025. The company reported -$1.71 earnings per share for the quarter, missing the consensus estimate of -$1.703 by -$0.007.

Is Kala Pharmaceuticals Inc overvalued?

According to Wall Street analysts Kala Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kala Pharmaceuticals Inc pay dividends?

Kala Pharmaceuticals Inc does not currently pay dividends.

What is Kala Pharmaceuticals Inc’s EPS estimate?

Kala Pharmaceuticals Inc’s EPS estimate is -1.41.

How many shares outstanding does Kala Pharmaceuticals Inc have?

Kala Pharmaceuticals Inc has 7,021,040 shares outstanding.

What happened to Kala Pharmaceuticals Inc’s price movement after its last earnings report?

Kala Pharmaceuticals Inc reported an EPS of -$1.71 in its last earnings report, missing expectations of -$1.703. Following the earnings report the stock price went up 3.073%.

Which hedge fund is a major shareholder of Kala Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in KALA

Kala Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-708.34%

Trailing 12-Months

Asset Growth

-41.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kala Pharmaceuticals Inc

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for eye diseases. The company primarily operates within the healthcare sector, specializing in ophthalmology. Its core products are designed to address unmet needs in ocular health, including treatments for dry eye disease and inflammation following ocular surgery.

Kala Pharmaceuticals (KALA) Earnings & Revenues

Historic Earnings Reports

KALA Stock 12 Month Forecast

Average Price Target

$8.25

▲(529.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.36,2.4092307692307693,3.4584615384615383,4.507692307692308,5.556923076923077,6.6061538461538465,7.655384615384615,8.704615384615384,9.753846153846153,10.803076923076922,11.852307692307692,12.901538461538461,13.950769230769229,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.36,1.8900000000000001,2.42,2.95,3.4800000000000004,4.010000000000001,4.54,5.07,5.6000000000000005,6.130000000000001,6.660000000000001,7.19,7.720000000000001,{"y":8.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.36,1.370769230769231,1.3815384615384616,1.3923076923076925,1.403076923076923,1.413846153846154,1.4246153846153846,1.4353846153846155,1.4461538461538461,1.456923076923077,1.4676923076923076,1.4784615384615385,1.4892307692307694,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >